Non-critically ill hospitalized Covid-19 patients could substantially benefit from a higher dose of blood-thinners

Giving noncritically ill patients hospitalized for COVID-19 a higher dose of blood-thinning medication than usual did not significantly reduce the combined risk of death from any cause, need for treatment in an intensive-care unit, a confirmed blood clot or a stroke at 30 days, according to the results of the FREEDOM-COVID trial presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology.